Patents by Inventor Dov Shiffman

Dov Shiffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210164050
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: January 10, 2020
    Publication date: June 3, 2021
    Inventors: Dov SHIFFMAN, James J. DEVLIN, Judy Z. LOUIE, Eric BOERWINKLE
  • Patent number: 10983108
    Abstract: Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 20, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Dov Shiffman, Carmen Tong, James J. Devlin, Michael J. McPhaul
  • Publication number: 20200270689
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Application
    Filed: December 27, 2019
    Publication date: August 27, 2020
    Inventors: Dov SHIFFMAN, May LUKE, David ROSS
  • Publication number: 20200248262
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Application
    Filed: December 16, 2019
    Publication date: August 6, 2020
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Patent number: 10584384
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: March 10, 2020
    Assignee: Celera Corporation
    Inventors: Dov Shiffman, James J. Devlin, Judy Z. Louie, Eric Boerwinkle
  • Patent number: 10563263
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: February 18, 2020
    Assignee: Celera Corporation
    Inventor: Dov Shiffman
  • Patent number: 10550433
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: February 4, 2020
    Assignees: The Brigham and Women's Hospital, Inc., Celera Corporation
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Publication number: 20190079070
    Abstract: Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Application
    Filed: March 30, 2018
    Publication date: March 14, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Dov Shiffman, Carmen Tong, James J. Devlin, Michael J. McPhaul
  • Publication number: 20190032136
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Application
    Filed: April 13, 2018
    Publication date: January 31, 2019
    Inventors: Dov SHIFFMAN, James J. DEVLIN, May LUKE, David ROSS
  • Publication number: 20170335394
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Application
    Filed: April 3, 2017
    Publication date: November 23, 2017
    Inventors: PAUL M. RIDKER, Daniel Chasman, Dov Shiffman
  • Publication number: 20170292159
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: January 18, 2017
    Publication date: October 12, 2017
    Inventors: Dov SHIFFMAN, James J. DEVLIN, Judy Z. LOUIE, Eric BOERWINKLE
  • Publication number: 20160108473
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Application
    Filed: August 25, 2015
    Publication date: April 21, 2016
    Inventors: Dov SHIFFMAN, James J. DEVLIN, May LUKE, David ROSS
  • Publication number: 20150284799
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Application
    Filed: November 6, 2014
    Publication date: October 8, 2015
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Publication number: 20140120533
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: August 12, 2013
    Publication date: May 1, 2014
    Applicant: Celera Corporation
    Inventors: Dov SHIFFMAN, James J. DEVLIN, Judy Z. LOUIE, Eric BOERWINKLE
  • Publication number: 20140024623
    Abstract: The invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Application
    Filed: January 15, 2013
    Publication date: January 23, 2014
    Applicants: Celera Corporation, The Brigham and Women's Hospital, Inc.
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Publication number: 20130030051
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: June 1, 2012
    Publication date: January 31, 2013
    Applicants: UNIVERSITY OF TEXAS BOARD OF REGENTS, CELERA CORPORATION
    Inventors: Dov SHIFFMAN, James J. DEVLIN, Judy Z. LOUIE, Eric BOERWINKLE
  • Patent number: 8216786
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: July 10, 2012
    Assignee: Celera Corporation
    Inventors: Dov Shiffman, James J. Devlin, Judy Z. Louie, Eric Boerwinkle
  • Publication number: 20110269735
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Application
    Filed: April 13, 2011
    Publication date: November 3, 2011
    Applicant: CELERA CORPORATION
    Inventors: Dov SHIFFMAN, James J. DEVLIN, May LUKE, David A. ROSS
  • Publication number: 20110206667
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Application
    Filed: April 19, 2011
    Publication date: August 25, 2011
    Applicants: The Brigham and Women's Hospital, Inc., Applera Corporation
    Inventors: Paul Ridker, Daniel Chasman, Dov Shiffman
  • Patent number: 7977052
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular stenosis and MI and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: July 12, 2011
    Assignee: Celera Corporation
    Inventors: May M. Luke, James J. Devlin, Dov Shiffman